马晓腾,吕赛,孙岩,申华,王志坚,高霏,刘晓丽,刘宇扬,史冬梅,周玉杰

• 1:首都医科大学附属北京安贞医院心血管内科北京市心肺血管疾病研究所

摘要(Abstract)：

<正>单纯主动脉瓣狭窄(aortic stenosis AS)很少由风湿性疾病引起,更多的是由瓣膜钙化所致,其中包括先天性二叶瓣畸形发生钙化导致的AS和老年退行性钙化病变导致的AS。前者主要发生在60岁以下的人群中,而后者多发生在合并多重心血管危险因素的老年人群中。随着年龄的增长,AS发病率逐渐增高,由50～59岁年龄组的0.2%上升到80～89岁年龄组的9.8%,其中绝大多数为钙化性AS(calcified aortic stenosis,CAS)~([1-2])。CAS是继冠状动脉旁路移植术后心脏外科手术第二大常见的适应证~([3]),也是发达国家最常见的心脏瓣膜病之一~([4])。预计CAS的发病率会随着全球老龄化的加剧而越来越高。我国目前还缺乏CAS相关的大型流行病学数据。

关键词(KeyWords)： 主动脉瓣狭窄;无症状;保守治疗;手术治疗

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(81670391);; 国家重点研发计划“精准医学研究”重点专项(2017YFC0908800);; 北京市医院管理局“登峰”计划专项经费资助(DFL20150601);北京市医院管理局“使命”计划专项经费资助(SML20180601)

作者(Author): 马晓腾,吕赛,孙岩,申华,王志坚,高霏,刘晓丽,刘宇扬,史冬梅,周玉杰

参考文献(References)：

• [1]Eveborn GW,Schirmer H,Heggelund G,et al.The evolving epidemiology of valvular aortic stenosis.the Tromso study.Heart,2013,99(6):396-400.
• [2]Otto CM,Prendergast B.Aortic-valve stenosis--from patients at risk to severe valve obstruction.N Engl J Med,2014,371(8):744-756.
• [3]Roberts WC,Ko JM.Frequency by decades of unicuspic,bicuspic,and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis,with or without associated aortic regurgitation.Circulation,2005,111(7):920-925.
• [4]Lindman BR,Clavel MA,Mathieu P,et al.Calcific aortic stenosis.Nat Rev Dis Primers,2016,2:16006.
• [5]Osnabrugge RL,Mylotte D,Head SJ,et al.Aortic stenosis in the elderly:disease prevalence and number of candidates for transcatheter aortic valve replacement:a meta-analysis and modeling study.J Am Coll Cardiol,2013,62(11):1002-1012.
• [6]Lund O,Nielsen TT,Emmertsen K,et al.Mortality and worsening of prognostic profile during waiting time for valve replacement in aortic stenosis.Thorac Cardiovasc Surg,1996,44(6):289-295.
• [7]Bates ER.Treatment options in severe aortic stenosis.Circulation,2011,124(3):355-359.
• [8 Nishimura RA,Otto CM,Bonow RO,et al.2014 AHA/ACC Guideline for the management of patients with valvular heart disease:executive summary:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol,2014,63(22):2438-2488.
• [9]Baumgartner H,Falk V,Bax JJ,et al.2017 ESC/EACTS Guidelines for the management of valvular heart disease.Eur Heart J,2017,38(36):2739-2791.
• [10]Genereux P,Stone GW,O'Gara PT,et al.Natural history,diagnostic approaches,and therapeutic strategies for patients with asymptomatic severe aortic stenosis.J Am Coll Cardiol,2016,67(19):2263-2288.
• [11]Redfors B,Pibarot P,Gillam LD,et al.Stress testing in asymptomatic aortic stenosis.Circulation,2017,135(20):1956-1976.
• [12]Gahl B,Celik M,Head S J,et al.Natural history of asymptomatic severe aortic stenosis and the association of early intervention with outcomes:a systematic review and meta-analysis.JAMA Cardiol,2020:e202497.
• [13]Perera S,Wijesinghe N,Ly E,et al.Outcomes of patients with untreated severe aortic stenosis in real-world practice.N Z Med J,2011,124(1345):40-48.
• [14]Gonzalez-Saldivar H,Rodriguez-Pascual C,de la Morena G,et al.Comparison of 1-year outcome in patients with severe aorta stenosis treated conservatively or by aortic valve replacement or by percutaneous transcatheter aortic valve implantation(data from a multicenter spanish registry).Am J Cardiol,2016,118(2):244-250.
• [15]van Le D,Jensen GV,Carstensen S,et al.Cardiopulmonaryexercise testing in patients with asymptomatic or equivocal symptomatic aortic stenosis:feasibility,reproducibility,safety and information obtained on exercise physiology.Cardiology,2016,133(3):147-156.
• [16]Nishimura RA,Otto CM,Bonow RO,et al.2017 AHA/ACC focused update of the 2014 AHA/ACC Guideline for the management of patients with valvular heart disease:a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.J Am Coll Cardiol,2017,70(2):252-289.
• [17]Guerbaii RA,Fustier G,Ennezat PV,et al.Asymptomatic aortic stenosis:An assessment of patients'and of their general practitioners'knowledge,after an indexed specialized assessment in community practice.PLoS One,2017,12(6):e0178932.
• [18]Brandenburg VM,Reinartz S,Kaesler N,et al.Slower progress of aortic valve calcification with vitamin K supplementation:results from a prospective interventional proof-of-concept study.Circulation,2017,135(21):2081-2083.
• [19]Cowell SJ,Newby DE,Prescott RJ,et al.A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis.N Engl J Med,2005,352(23):2389-2397.
• [20]Rossebo AB,Pedersen TR,Boman K,et al.Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.N Engl J Med,2008,359(13):1343-1356.
• [21]Chan KL,Teo K,Dumesnil JG,et al.Effect of lipid lowering with rosuvastatin on progression of aortic stenosis:results of the aortic stenosis progression observation:measuring effects of rosuvastatin(ASTRONOMER)trial.Circulation,2010,121(2):306-314.
• [22]Thanassoulis G,Campbell CY,Owens DS,et al.Genetic associations with valvular calcification and aortic stenosis.N Engl JMed,2013,368(6):503-512.
• [23]Otto CM,Kuusisto J,Reichenbach DD,et al.Characterization of the early lesion of'degenerative'valvular aortic stenosis.Histological and immunohistochemical studies.Circulation,1994,90(2):844-853.
• [24] Perrot N,Theriault S,Dina C,et al.Genetic variation in LPA,calcific aortic valve stenosis in patients undergoing cardiac surgery,and familial risk of aortic valve microcalcification.JAMA Cardiol,2019,4(7):620-627.
• [25]Zheng KH,Tsimikas S,Pawade T,et al.Lipoprotein(a)and oxidized phospholipids promote valve calcification in patients with aortic stenosis.J Am Coll Cardiol,2019,73(17):2150-2162.
• [26] Gotoh T,Kuroda T,Yamasawa M,et al.Correlation between lipoprotein(a)and aortic valve sclerosis assessed by echocardiography(the JMS Cardiac Echo and Cohort Study).Am J Cardiol,1995,76(12):928-932.
• [27]Stewart BE,Siscovick D,Lind BK,et al.Clinical factors associated with calcific aortic valve disease.Cardiovascular Health Study.J Am Coll Cardiol,1997,29(3):630-634.
• [28]Kamstrup PR,Tybjaerg-Hansen A,Nordestgaard BG.Elevated lipoprotein(a)and risk of aortic valve stenosis in the general population.J Am Coll Cardiol,2014,63(5):470-477.
• [29]Capoulade R,Chan KL,Yeang C,et al.Oxidized phospholipids,lipoprotein(a),and progression of calcific aortic valve stenosis.J Am Coll Cardiol,2015,66(11):1236-1246.
• [30]Small A,Kiss D,Giri J,et al.Biomarkers of calcific aortic valve disease.Arterioscler Thromb Vase Biol,2017,37(4):623-632.
• [31]Borrelli MJ,Youssef A,Boffa MB,et al.New frontiers in Lp(a)-targeted therapies.Trends Pharmacol Sci,2019,40(3):212-225.
• [32]Tsimikas S,Karwatowska-Prokopczuk E,Gouni-Berthold I,et al.Lipoprotein(a)reduction in persons with cardiovascular disease.N Engl J Med,2020,382(3):244-255.
• [33]Viney NJ,van Capelleveen JC,Geary RS,et al.Antisense oligonucleotides targeting apolipoprotein(a)in people with raised lipoprotein(a):two randomised,double-blind,placebo-controlled,dose-ranging trials.Lancet,2016,3 88(10057):2239-2253.
• [34]Saeed S,Mancia G,Rajani R,et al.Antihypertensive treatment with calcium channel blockers in patients with moderate or severe aortic stenosis:Relationship with all-cause mortality.Int J Cardiol,2020,298:122-125.
• [35]Bang CN,Greve AM,Rosseb0 AB,et al.Antihypertensive treatment withβ-blockade in patients with asymptomatic aortic stenosis and association with cardiovascular events.J Am Heart Assoc,2017,6(12):e006709.
• [36]Capoulade R,Clavel MA,Mathieu P,et al.Impact of hypertension and renin-angiotensin system inhibitors in aortic stenosis.Eur I Clin Invest,2013,43(12):1262-1272.
• [37]Nadir MA,Wei L,Elder DH,et al.Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis.J Am Coll Cardiol,2011,58(6):570-576.
• [38]Bang CN,Greve AM,Kober L,et al.Renin-angiotensin system inhibition is not associated with increased sudden cardiac death,cardiovascular mortality or all-cause mortality in patients with aortic stenosis.Int J Cardiol,2014,175(3):492-498.
• [39]Bull S,Loudon M,Francis JM,et al.A prospective,doubleblind,randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis(RIAS trial).Eur Heart J Cardiovasc Imaging,2015,16(8):834-841.
• [40]Mancusi C,de Simone G,Hitij JB,et al.Management of patients with combined arterial hypertension and aortic valve stenosis:a consensus document from the Council on Hypertension and Council on Valvular Heart Disease of the European Society of Cardiology,the European Association of Cardiovascular Imaging(EACVI),the European Association of Percutaneous Cardiovascular Interventions(EAPCI).Eur Heart J Cardiovasc Pharmacother,2020:pvaa040.
• [41]Lund O.Preoperative risk evaluation and stratification of long-term survival after valve replacement for aortic stenosis.Reasons for earlier operative intervention.Circulation,1990,82(1):124-139.
• [42]Siontis GCM,Overtchouk P,Cahill TJ,et al.Transcatheter aortic valve implantation vs.surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis:an updated meta-analysis.Eur Heart J,2019,40(38):3143-3153.
• [43]Lindman BR,Dweck MR,Lancellotti P,et al.Management of asymptomatic severe aortic stenosis:evolving concepts in timing of valve replacement.JACC Cardiovasc Imaging,2020,13(2 Pt 1):481-493.
• [441 Le Tourneau T,Pellikka PA,Brown ML,et al.Clinical outcome of asymptomatic severe aortic stenosis with medical and surgical management:importance of STS score at diagnosis.Ann Thorac Surg,2010,90(6):1876-1883.
• [45] Pellikka PA,Sarano ME,Nishimura RA,et al.Outcome of 622 adults with asymptomatic,hemodynamically significant aortic stenosis during prolonged follow-up.Circulation,2005,111(24):3290-3295.
• [46]Taniguchi T,Morimoto T,Shiomi H,et al.Initial surgical versus conservative strategies in patients with asymptomatic severe aortic stenosis.J Am Coll Cardiol,2015,66(25):2827-2838.
• [47]Tastet L,Simard L,Clavel MA.Severe and asymptomatic aortic stenosis management challenge:knowing that we do not really know.Curr Treat Options Cardiovasc Med,2017,19(5):33.
• [48]Baumgartner H,Falk V,Bax JJ,et al.2017 ESC/EACTS Guidelines for the management of valvular heart disease:The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology(ESC)and the European Association for Cardio-Thoracic Surgery(FACTS)Eur Heart J,2018,39(3):213-260.
• [49]Le VDT.Cardiopulmonary exercise testing in aortic stenosis.Dan Med J,2017,64(5):B5352.
• [50] Otto CM,Kumbhani DJ,Alexander KP,et al.2017 ACC expert consensus decision pathway for transcatheter aortic valve replacement in the management of adults with aortic stenosis:a report of the American college of cardiology task force on clinical expert consensus documents.J Am Coll Cardiol,2017,69(10):1313-1346.
• [51]Doguet F,Godin M,Lebreton G,et al.Aortic valve replacement after percutaneous valvuloplasty--an approach in otherwise inoperable patients.Eur JCardiothorac Surg,2010,38(4):394-399.
• [52]No authors listed.Percutaneous balloon aortic valvuloplasty.Acute and 30-day follow-up results in 674 patients from the NHLBI balloon valvuloplasty registry.Circulation,1991,84(6):2383-2397.
• [53]Otto CM,Mickel MC,Kennedy JW,et al.Three-year outcome after balloon aortic valvuloplasty.Insights into prognosis of valvular aortic stenosis.Circulation,1994,89(2):642-650.
• [54]中华医学会心血管病学分会结构性心脏病学组,中国医师协会心血管内科医师分会结构性心脏病专业委员会.中国经导管主动脉瓣置换术临床路径专家共识.中国介入心脏病学杂志,2018,26(12):661-668.
• [55]Ak A,Porokhovnikov I,Kuethe F,et al.Transcatheter vs.surgical aortic valve replacement and medical treatment:systematic review and meta-analysis of randomized and nonrandomized trials.Herz,2018,43(4):325-337.
• [56]Takagi H,Ando T,Umemoto T.Direct and adjusted indirect comparisons of perioperative mortality after sutureless or rapiddeployment aortic valve replacement versus transcatheter aortic valve implantation.Int J Cardiol,2017,228:327-334.
• [57]Kang DH,Park SJ,Lee SA,et al.Early surgery or conservative care for asymptomatic aortic stenosis.N Engl J Med,2020,382(2):111-119.
• [58]Banovic M,lung B,Bartunek J,et al.Rationale and design of the aortic valve replacement versus conservative treatment in asymptomatic severe aortic stenosis(AVATAR trial):a randomized multicenter controlled event-driven trial.Am Heart J,2016,174:147-153.
• [59]Banovic M,lung B,Bartunek J,et al.The aortic valve replacement versus conservative treatment in asymptomatic severe aortic stenosis(AVATAR trial):a protocol update.Am Heart J,2018,195:153-154.
• [60]Bing R,Everett RJ,Tuck C,et al.Rationale and design of the randomized,controlled early valve replacement guided by biomarkers of left ventricular decompensation in asymptomatic patients with severe aortic stenosis(EVOLVED)trial.Am Heart J,2019,212:91-100.